Immunogenicity and protective activity of mRNA vaccine candidates against yellow fever virus in animal models
Open Access
- 4 March 2023
- journal article
- research article
- Published by Springer Nature in npj Vaccines
- Vol. 8 (1) , 1-13
Abstract
Despite the success of the widely used attenuated yellow fever (YF) vaccine, its global supply remains a substantial barrier to implementing vaccination campaigns in endemic regions and combating emerging epidemics. In A129 mice and rhesus macaques, we evaluated the immunogenicity and protective activity of messenger RNA (mRNA) vaccine candidates encapsulated in lipid nanoparticles, expressing the pre-membrane and envelope proteins or the non-structural protein 1 of YF virus. Vaccine constructs induced humoral and cell-mediated immune responses in mice, resulting in protection against lethal YF virus infection after passive administration of serum or splenocytes from vaccinated mice. Vaccination of macaques induced sustained high humoral and cellular immune responses for at least 5 months after the second dose. Our data demonstrate that these mRNA vaccine candidates can be considered an attractive addition to the licensed YF vaccine supply based on the induction of functional antibodies correlating with protection and T-cell responses; they could alleviate the limited supply of current YF vaccines, mitigating future YF epidemics.Keywords
Funding Information
- Coalition for Epidemic Preparedness Innovations
This publication has 51 references indexed in Scilit:
- Efficacy and Duration of Immunity after Yellow Fever Vaccination: Systematic Review on the Need for a Booster Every 10 YearsThe American Journal of Tropical Medicine and Hygiene, 2013
- Advanced Yellow Fever Virus Genome Detection in Point-of-Care Facilities and Reference LaboratoriesJournal of Clinical Microbiology, 2012
- The Safety of Yellow Fever Vaccine 17D or 17DD in Children, Pregnant Women, HIV+ Individuals, and Older Persons: Systematic ReviewThe American Journal of Tropical Medicine and Hygiene, 2012
- Efficacy and safety of a modified vaccinia Ankara (MVA) vectored plague vaccine in miceVaccine, 2010
- A Mouse Model for Studying Viscerotropic Disease Caused by Yellow Fever Virus InfectionPLOS Pathogens, 2009
- Antibody Recognition of Cell Surface-Associated NS1 Triggers Fc-γ Receptor-Mediated Phagocytosis and Clearance of West Nile Virus-Infected CellsJournal of Virology, 2007
- Vaccines: All Things ConsideredClinical and Vaccine Immunology, 2006
- The vaccine adverse event reporting system (VAERS)Vaccine, 1994
- MVA-Stufenimpfung gegen PockenDMW - Deutsche Medizinische Wochenschrift, 1974
- THE EFFECT OF PROLONGED CULTIVATION IN VITRO UPON THE PATHOGENICITY OF YELLOW FEVER VIRUSJournal of Experimental Medicine, 1937